Carboline, diketopiperazine, and purine derivatives for oncology drug discovery targeting p53, integrins, and cadherins

Overview

This research program delivers three complementary small-molecule scaffold families aimed at key oncology targets. Carboline derivatives are designed as MDM2 inhibitors to reactivate the p53 tumor suppressor pathway. Diketopiperazine (DKP) compounds are engineered as integrin ligands, with potential applications as angiogenesis inhibitors or as homing receptor ligands on tumor cells. A purine derivative, specifically a 6-unsubstituted, C-2 substituted purine, is synthesized through a novel metal-halogen exchange methodology that opens new routes to this molecular class. Together, these scaffolds offer a versatile toolkit for hit-to-lead development in cancer therapeutics.

Technical specifications

Carboline derivatives as MDM2 inhibitors:

• Designed to disrupt the p53-MDM2 protein-protein interaction, restoring p53-mediated tumor suppression
• Based on the carboline scaffold as a starting point for new chemical entities
• Potential applications in oncology drug development targeting the p53 pathway

Diketopiperazine (DKP) derivatives as integrin and cadherin ligands:

• DKP scaffold acts as a beta-turn inducer, imposing a specific conformation on the cyclic peptidomimetic
• Designed to bind integrins as angiogenesis inhibitors or as homing receptor ligands on tumor cells
• Additional potential as cadherin ligands for cell adhesion modulation

Purine derivative via novel metal-halogen exchange:

• 6-unsubstituted, C-2 substituted purines represent a novel molecular scaffold class
• Produced using a new metal-halogen exchange methodology that may enable broader access to substituted purine libraries

Technology readiness level

These compounds are at an early discovery stage. The research hypothesis is based on established scaffold design principles: beta-turn induction for DKP peptidomimetics, carboline-based MDM2 inhibition, and novel purine substitution patterns. The next steps involve experimental validation of binding affinity and biological activity for each scaffold family, followed by hit optimization and structure-activity relationship studies to advance candidates toward preclinical evaluation.